



# Technical Alert

## Geenius™ HIV 1/2 Supplemental Assay

---

**TO:** Physicians, Clinical Staff and Clients

**FROM:** Dr. Matthew J. Bankowski, PhD, D(ABMM), HCLD/CC(ABB)  
V.P. – Technical Director, Clinical and Molecular Microbiology and Infectious Disease

Susan Krause, B.S., MT(ASCP) - Manager, DLS Core Laboratory

Dr. Wesley Kim, M.D.    Dr. Ana Ortega-Lopez, M.D.    Dr. Rosalyn Enos, MD  
DLS Laboratory Director    Laboratory Director, QMC    QMC West Laboratory Director  
North Hawaii and Molokai

**DATE:** October 10, 2016

**SUBJECT:** The “Geenius™ HIV 1/2 Supplemental Assay” will replace the “Multispot HIV-1/HIV-2 Rapid Test”.

---

Effective as of **October 13, 2016**, the Geenius™ HIV 1/2 Supplemental Assay will replace the Multispot HIV-1/HIV-2 Rapid Test reflex assay. The reason for this change in methodology is due to the discontinuance of the Multispot test. The intended use is similar to the Multispot. The Geenius™ HIV 1/2 Supplemental Assay is an additional, more specific test to confirm the presence of antibodies to HIV-1 and HIV-2 for specimens found to be repeatedly reactive by diagnostic screening procedures.

The Geenius™ HIV 1/2 Supplemental Assay is comparable in test performance to the previously used Multispot HIV-1/HIV-2 Rapid Test reflex test. There is no change in the test code or the reporting format with this replacement assay and the test report will appear identical.

Please refer any questions to Susan Krause, Manager - DLS Core Laboratory at 589-5126, or DLS Client Services at 589-5101.